Invirsa develops global patent portfolio directed to INV-102
Client(s) Invirsa, Inc.
Jones Day represents Invirsa, Inc. in the establishment of a global patent portfolio related to INV-102, a small molecule immune response modulator.
Cases & Deals
Contacts
Practices
Locations
Before sending, please note:
Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.